The In Vitro Diagnostic Regulation (IVDR) represents a significant milestone in the European Union’s regulatory landscape for medical devices. Its implementation brings forth substantial changes, particularly affecting clinical trial assays. Understanding these changes and adapting accordingly is crucial for ensuring compliance and maintaining the integrity of clinical trial data. In this comprehensive guide, we’ll delve into the key aspects of IVDR and explore its impact on clinical trial assays.
Understanding IVDR: a brief overview
The IVDR, introduced by the European Union (EU), came into effect on May 26, 2022, replacing the previously established In Vitro Diagnostic Directive (IVDD). With increased regulatory oversight, the IVDR encompasses more stringent requirements for the designation of Notified Bodies (NBs) and monitoring by the national competent authorities and the Commission. In 2022, the EU will enforce the transition from the current In Vitro Diagnostic Medical Devices Directive 98/79/EC (IVDD) to the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR) for clinical diagnostic applications. This means that from May 26, 2022, any new IVD devices placed on the market must be CE marked according to IVDR.
Key changes introduced by IVDR
- Classification system: IVD Regulation introduces a risk-based classification system for IVDs, which categorizes devices into four classes (A, B, C, and D) based on their inherent risk. This classification directly impacts the conformity assessment process and the level of scrutiny required for obtaining CE marking.
- Conformity assessment: Unlike the IVDD, which relied heavily on self-certification, IVDR mandates the involvement of notified bodies for most devices. This entails a more rigorous conformity assessment process, involving scrutiny of technical documentation, performance evaluation, and quality management systems.
- Performance evaluation: IVDR places greater emphasis on the performance evaluation of IVDs, requiring manufacturers to provide comprehensive and robust clinical evidence to support the device’s analytical and clinical performance claims. This involves conducting clinical studies or utilizing existing clinical data to demonstrate the device’s safety and effectiveness.
- Post-market surveillance: New regulation strengthens post-market surveillance requirements, necessitating manufacturers to establish proactive monitoring systems to collect and analyze real-world data on device performance and safety. This includes the implementation of vigilance and trend reporting mechanisms to promptly identify and address any issues that may arise post-market.
Impact on clinical trial assays
The implementation of IVDR has profound implications for clinical trial assays, particularly those involving IVDs. Some of the key impacts include:
- Increased Regulatory Scrutiny: With the introduction of stricter conformity assessment procedures and performance evaluation requirements, clinical trial assays involving IVDs are subjected to increased regulatory scrutiny. Manufacturers must ensure compliance with their stringent requirements throughout the development and validation process.
- Clinical Evidence Requirements: IVDR mandates the generation of robust clinical evidence to support the performance claims of IVDs. This necessitates the conduct of well-designed clinical studies to demonstrate the assay’s analytical and clinical performance characteristics. Moreover, existing clinical data may need to be re-evaluated and supplemented to meet new regulation’s evidentiary standards.
- Data Management and Documentation: The documentation requirements under IVDR are more extensive compared to the IVDD. Manufacturers must maintain comprehensive records of all aspects of the assay development, validation, and performance evaluation process. This includes detailed documentation of study protocols, data collection procedures, and analysis methods.
- Post-Market Surveillance Obligations: IVDR imposes stringent post-market surveillance obligations on manufacturers, requiring them to actively monitor the performance and safety of their assays in real-world settings. This involves the establishment of robust vigilance and trend reporting systems to facilitate timely identification and resolution of any issues that may arise post-market.
Support for pharma companies with IVDR-compliant qPCR assays
At MICS, we understand the pivotal role that reliable and compliant assays with all international regulations play in the success of clinical trials. One of our research areas we support pharma and biotech companies are genomic studies. Our commitment to excellence in developing quantitative Polymerase Chain Reaction (qPCR) and droplet digital PCR (ddPCR) assays is unmatched, especially under the stringent requirements of the In Vitro Diagnostic Regulation in the European Union.
For pharmaceutical companies and biotech firms crucial is to choose trusted partner in establishing qPCR assays for clinical trials. Contact us to get more information
Assay Development and Validation
Custom Assay Design and Optimization: We have the ability to design and optimize qPCR and ddPCR assays tailored to the unique needs of your clinical trials. Our team of experts selects primers and probes, optimizes reaction conditions, and ensures that our assays are both sensitive and specific to your target genetic material. Our approach guarantees the development of robust assays that deliver accurate and reproducible results.
Validation According to IVD Regulation Standards: Our stringent validation process ensures that all qPCR and ddPCR assays meet the rigorous standards set by the IVDR. We conduct comprehensive validation studies to demonstrate assay performance characteristics such as accuracy, precision, specificity, sensitivity, and reproducibility. By doing so, we provide you with confidence that our assays are reliable and compliant with regulatory expectations.
Learn more about how we support pharma, CROs, and biotech companies in ensuring regulatory compliance within clinical trials.
Summary
The implementation of The In Vitro Diagnostic Regulation represents a significant paradigm shift in the regulation of IVDs within the EU. Its impact on clinical trial assays is profound, necessitating compliance with stricter conformity assessment procedures, enhanced performance evaluation requirements, and rigorous post-market surveillance obligations. By understanding and proactively addressing these changes, manufacturers can navigate the complexities of IVDR effectively while ensuring the integrity and reliability of their clinical trial data.
Learn more: 11 Frequently Asked Questions (FAQ) about IVDR regulation
FAQ
1. What is the IVDR and why was it introduced?
The In Vitro Diagnostic Regulation (IVDR) is the European Union’s updated legal framework governing diagnostic tests. It was introduced to improve patient safety, increase transparency, and ensure that in vitro diagnostic devices meet stricter performance and quality requirements compared to the previous IVDD directive.
2. When did IVDR come into effect?
The regulation officially became applicable on May 26, 2022. From that date onward, newly placed IVD devices must comply with IVDR, including CE marking based on the updated conformity assessment rules.
3. How does IVDR affect clinical trial assays?
IVDR increases regulatory scrutiny for any assay used in clinical studies. This means manufacturers must provide more extensive documentation, stronger clinical evidence, validated performance characteristics, and maintain post-market surveillance activities throughout the assay’s lifecycle.
4. What are the key performance criteria required under IVDR?
IVDR requires evidence of:
– Accuracy
– Precision
– Specificity
– Sensitivity
– Analytical validity
– Reproducibility
These parameters ensure assays deliver reliable data in real-world clinical settings.
5. Why are notified bodies more involved under IVDR?
Unlike the IVDD, which allowed broader self-certification, IVDR requires Notified Body oversight for most devices. These independent organizations evaluate technical files, performance studies, quality management systems, and risk assessments before a device can be CE marked.
***
Author: MICS Editorial Team
Published Date: July 2024
References:
- Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)
- Official document: Regulation (EU) 2017/746
- European Commission – New regulations on medical devices
- Information on new regulations: IVDR – Regulation (EU) 2017/746
- European Medicines Agency – In vitro diagnostics
- Detailed information from EMA: In vitro diagnostics
- The European Union In Vitro Diagnostics Regulation
- Regulation (EU) 2017/746 (EU IVDR)
- Factsheet for manufacturers of in vitro diagnostic.
- Getting ready for the new regulations – European Commission (europa.eu)
